Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Depreciation & Amortization (CF): 2011-2024

Historic Depreciation & Amortization (CF) for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $8.0 million.

  • Adma Biologics' Depreciation & Amortization (CF) rose 4.28% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 2.63%. This contributed to the annual value of $8.0 million for FY2024, which is 3.44% down from last year.
  • Per Adma Biologics' latest filing, its Depreciation & Amortization (CF) stood at $8.0 million for FY2024, which was down 3.44% from $8.3 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Depreciation & Amortization (CF) registered a high of $8.3 million during FY2023, and its lowest value of $3.9 million during FY2020.
  • Over the past 3 years, Adma Biologics' median Depreciation & Amortization (CF) value was $8.0 million (recorded in 2024), while the average stood at $7.8 million.
  • As far as peak fluctuations go, Adma Biologics' Depreciation & Amortization (CF) soared by 39.41% in 2021, and later declined by 3.44% in 2024.
  • Over the past 5 years, Adma Biologics' Depreciation & Amortization (CF) (Yearly) stood at $3.9 million in 2020, then spiked by 39.41% to $5.5 million in 2021, then climbed by 29.42% to $7.1 million in 2022, then increased by 17.14% to $8.3 million in 2023, then decreased by 3.44% to $8.0 million in 2024.